Desarrollo de herramienta informática para el fácil acceso a tratamientos farmacológicos en neurología

Justificación: Muchas veces son médicos y/o especialistas en proceso de formación, médicos generales en urgencias y consulta externa, o especialidades como Medicina de Urgencias, Medicina Interna, Neurocirugía y/o Neurología los primeros respondientes, en muchos casos sin el entrenamiento suficiente...

Full description

Autores:
Hernández Rojas, Enrique Steff
Tipo de recurso:
Work document
Fecha de publicación:
2020
Institución:
Universidad Nacional de Colombia
Repositorio:
Universidad Nacional de Colombia
Idioma:
spa
OAI Identifier:
oai:repositorio.unal.edu.co:unal/75570
Acceso en línea:
https://repositorio.unal.edu.co/handle/unal/75570
Palabra clave:
Medicina y salud
Neurology
Treatment
Application
Drugs
Neurología
Tratamiento
Aplicación
Medicamentos
App
Rights
openAccess
License
Atribución-NoComercial-SinDerivadas 4.0 Internacional
id UNACIONAL2_dcb72d9b58624ebc52fa31285d8c52d6
oai_identifier_str oai:repositorio.unal.edu.co:unal/75570
network_acronym_str UNACIONAL2
network_name_str Universidad Nacional de Colombia
repository_id_str
dc.title.spa.fl_str_mv Desarrollo de herramienta informática para el fácil acceso a tratamientos farmacológicos en neurología
title Desarrollo de herramienta informática para el fácil acceso a tratamientos farmacológicos en neurología
spellingShingle Desarrollo de herramienta informática para el fácil acceso a tratamientos farmacológicos en neurología
Medicina y salud
Neurology
Treatment
Application
Drugs
Neurología
Tratamiento
Aplicación
Medicamentos
App
title_short Desarrollo de herramienta informática para el fácil acceso a tratamientos farmacológicos en neurología
title_full Desarrollo de herramienta informática para el fácil acceso a tratamientos farmacológicos en neurología
title_fullStr Desarrollo de herramienta informática para el fácil acceso a tratamientos farmacológicos en neurología
title_full_unstemmed Desarrollo de herramienta informática para el fácil acceso a tratamientos farmacológicos en neurología
title_sort Desarrollo de herramienta informática para el fácil acceso a tratamientos farmacológicos en neurología
dc.creator.fl_str_mv Hernández Rojas, Enrique Steff
dc.contributor.advisor.spa.fl_str_mv Fernández Escobar, William
dc.contributor.author.spa.fl_str_mv Hernández Rojas, Enrique Steff
dc.subject.ddc.spa.fl_str_mv Medicina y salud
topic Medicina y salud
Neurology
Treatment
Application
Drugs
Neurología
Tratamiento
Aplicación
Medicamentos
App
dc.subject.proposal.eng.fl_str_mv Neurology
Treatment
Application
Drugs
dc.subject.proposal.spa.fl_str_mv Neurología
Tratamiento
Aplicación
Medicamentos
App
description Justificación: Muchas veces son médicos y/o especialistas en proceso de formación, médicos generales en urgencias y consulta externa, o especialidades como Medicina de Urgencias, Medicina Interna, Neurocirugía y/o Neurología los primeros respondientes, en muchos casos sin el entrenamiento suficiente y la afinidad necesaria por las neurociencias, para afrontar la complejidad que puede representar una enfermedad neurológica. Una herramienta informática, diseñada como aplicación (“app”) para dispositivos móviles, representa un material valioso para profesionales de la salud, estudiantes y, por supuesto, beneficioso para pacientes. Uno de los motivos por los cuales se plantea el desarrollo de este proyecto, es el hecho de no haber encontrado aplicaciones móviles centradas en el manejo farmacológico de enfermedades neurológicas en búsquedas previamente realizadas. La necesidad de una guía práctica enfocada en este aspecto lo convierte en una herramienta innovadora. Objetivo: Desarrollar una herramienta informática a manera de aplicación móvil, con la finalidad de guiar al profesional de la salud en el manejo farmacológico de las enfermedades neurológicas más prevalentes. Metodología: Se buscó sistemáticamente tratamientos farmacológicos recientes y actualizados en enfermedades neurológicas, teniendo en cuenta guías europeas, americanas y colombianas. Se diseñó una interfaz disponible para dispositivos móviles que cuenten con sistema operativo Android, en idioma español. Resultados: Creación de aplicación móvil ‘NeuroDosis’, brindando información concisa para la asistencia en la toma de decisiones por parte del clínico. Explicación breve del arsenal farmacológico indicado (mecanismo de acción, dosis, efectos adversos más frecuentes, contraindicaciones y recomendaciones prácticas) en las patologías neurológicas más prevalentes en pacientes adultos.
publishDate 2020
dc.date.accessioned.spa.fl_str_mv 2020-02-10T14:59:25Z
dc.date.available.spa.fl_str_mv 2020-02-10T14:59:25Z
dc.date.issued.spa.fl_str_mv 2020-02-06
dc.type.spa.fl_str_mv Documento de trabajo
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/workingPaper
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_8042
dc.type.content.spa.fl_str_mv Text
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/WP
format http://purl.org/coar/resource_type/c_8042
status_str acceptedVersion
dc.identifier.uri.none.fl_str_mv https://repositorio.unal.edu.co/handle/unal/75570
url https://repositorio.unal.edu.co/handle/unal/75570
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.references.spa.fl_str_mv 1. Huckvale K, Prieto JT, Tilney M, Benghozi PJ, Car J. Unaddressed privacy risks in accredited health and wellness apps: A crosssectional systematic assessment. BMC Med. 2015;13:214. 2. Oh, H., Rizo, C., Enkin, M., Jadad, A. (2005). What is eHealth (3): A Systematic Review of Published Definitions. Journal of Medical Internet Research, 7(1), e1. 3. Pradilla A., G., Vesga A., B. E., & León-Sarmiento, F. E. (2003). Estudio neuroepidemiológico nacional (EPINEURO) colombiano. Revista Panamericana de Salud Pública, 14(2), 104–111. 4. Restrepo, J., Aldana, R., Álvarez, et. Al (2017). Percepción de neurofobia en estudiantes de último año de Medicina en una universidad privada Neurophobic perception in last year medical students at a private university. Acta Neurológica Colombiana, 33(1), 63–67. 5. Jozefowicz R. Neurophobia: The Fear of Neurology Among Medical Students. Archives of Neurology. 1994;51(4):328-29. 6. Moringo D, Fleitas D, Morel Pirelli M, V. G. (2017). Neurofobia en estudiantes de postgrado en Medicina Interna. Rev. Virtual Soc. Parag. Med. Int., 04(2), 42–48. 7. Dorsey, E. R., Chan, Y. F., Mcconnell, M. V., Shaw, S. Y., Trister, A. D., & Friend, S. H. (2017). The use of smartphones for health research. Academic Medicine, 92(2), 157–160. 8. Albers GW, Alberts MJ, Chaturvedi S, Feldmann F; E, Hatsukami TS, Higashida RT, et al. Definition and Evaluation of Transient Ischemic Attack A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiov. AHA/ASA Sci Statement. 2009;40:2276–93. 9. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Vol. 50, Stroke. 2019. 344–418 p. 10. Prasad K, Siemieniuk R, Hao Q, Guyat G, O’Donnell M, Lytvyn L, et al. Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. BMJ Rapid Recomm. 2018; 11. Amarenco P, Labreuche J, Lavallée P, Touboul P-J. Statins in Stroke Prevention and Carotid Atherosclerosis Systematic Review and Up-to-Date Meta-Analysis. 2004; 12. Amarenco P, Diderot Uni-versity D, Bogousslavsky J, Rudolph AE, York N, Sillesen H, et al. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators* A BS TR AC T. 2006. 13. Rabinstein AA. Tratamiento Agudo De Evc Isquemico. Continuum (N Y). 2017;(February):62–81. 14. Coutts SB. Diagnosis and Management of Transient Ischemic Attack. Contin Lifelong Learn Neurol. 2017;23(1):82–92. 15. Demaerschalk BM. Remote Evaluation of the Patient with Acute Stroke. Contin Lifelong Learn Neurol. 2017;23(1):259–67. 16. Cj D, Derry S, Ra M. Sumatriptan (all routes of administration) for acute migraine attacks in adults-overview of Cochrane reviews (Review). 2014; 17. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat P Tfelt-Hansen. Cephalalgia. 1998;532–8. 18. Bird S, Derry S, Ra M. Zolmitriptan for acute migraine attacks in adults (Review). cochrane. 2014; 19. Brandes JL, Kudrow D, Stark SR, Phillip O’carroll C, Adelman JU, O’donnell FJ, et al. Sumatriptan-Naproxen for Acute Treatment of Migraine A Randomized Trial. Vol. 297, JAMA. 2007. 20. Vane J. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drug. Vol. 231, Nature new biology. 1971. 21. Taggart E, Doran S, Kokotillo A, Campbell S, Villa-Roel C, Rowe BH, et al. Ketorolac in the Treatment of Acute Migraine: A Systematic Review. Am Headache Soc. 2013; 22. Derry S, Ra M. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults (Review). Cochrane Database Syst Rev. 2013; 23. Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E, et al. Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient SECTION III. Can J Neurol Sci. 2013;s33–62. 24. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous Dipyrone in the Acute Treatment of Migraine Without Aura and Migraine with Aura: A Randomized, Double Blind, Placebo Controlled Study. Headache. 2002;42:862–71. 25. Hering R, Couturier E, Steiner T. Intramuscular diclofenac in late treatment of migraine. 1996. 26. Engindeniz Z, Demircan C, Karli N, Armagan E, Bulut M, Aydin T, et al. Intramuscular tramadol vs. diclofenac sodium for the treatment of acute migraine attacks in emergency department: a prospective, randomised, double-blind study. headache Pain. 2005;6:143–8. 27. Muñoz J, Volcy M, Sobrino F, Ramirez S, Uribe B, Pradilla G, et al. Consenso de expertos de la Asociación Colombiana de Neurología para el tratamiento preventivo y agudo de la migraña Expert consensus on the preventive and acute treatment of migraine on behalf of the Colombian Association of Neurology Artículo original. Vol. 30, Acta Neurol Colomb. 2014. 28. Silberstein SD, Mccrory DC. Ergotamine and Dihydroergotamine: History, Pharmacology, and Efficacy. Headache. 2003. 29. Langer-Gould AM, Anderson WE, Armstrong MJ, Cohen AB, Eccher MA, Iverson DJ, et al. The American Academy of Neurology’s Top Five Choosing Wisely recommendations. Am Acad ofNeurology. 2013;81:1004–11. 30. Blumenfeld A, Ashkenazi A, Napchan U, Bender SD, Klein BC, Berliner R, et al. Expert Consensus Recommendations for the Performance of Peripheral Nerve Blocks for Headaches-A Narrative Review. Headache. 2013;53:437–46. 31. Robbins MS, Robertson CE, Kaplan E, Ailani J, Charleston L, Kuruvilla D, et al. The Sphenopalatine Ganglion: Anatomy, Pathophysiology, and Therapeutic Targeting in Headache. Headache. 2015;56:240–58. 32. Colman I, Friedman BW, Brown MD, Innes G, Grafstein E, Roberts TE, et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BJM. 2008;1–7. 33. Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, et al. Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache. 2016;56:911–40. 34. Vécsei L, Szok D, Nyári A, Tajti J. Treating status migrainosus in the emergency setting: what is the best strategy? Expert Opin Pharmacother. 2018;1–9. 35. Demirkaya eref, Vural O, Dora B, Akif Topçuo lu M. Efficacy of Intravenous Magnesium Sulfate in the Treatment of Acute Migraine Attacks. Headache. 2001;41:171–7. 36. Bigal ME, Bordini CA, Speciali JG. intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med. 2002;23(2):141–8. 11 37. Léger P, Lortie G. Towards evidence-based emergency medicine: metoclopramide or prochlorperazine for headache in acute migraine? Emerg Med J. 2013;30:595–6. 38. Friedman BW, Eddie Irizarry M, Solorzano C, Alexander Latev P, Rosa K, Zias E, et al. Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. Neurology. 2017;89:1–8. 39. Colman I, Brown MD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004;1–5. 40. Honkaniemi J, Liimatainen S, Rainesalo S, Sulavuori S. Haloperidol in the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache. 2006;46:781–7. 41. The International Classification of Headache Disorders, 3rd edition Copyright. Cephalalgia. 2018;38:1–211. 42. Pringsheim T, Davenport WJ, Mackie G, Worthington I, Aubé M, Christie SN, et al. Canadian Headache Society Guideline for Migraine Prophylaxis. Vol. 39. 2012. 43. Shamliyan TA, Choi J-Y, Ramakrishnan R, Biggs Miller J, Wang S-Y, Taylor FR, et al. Preventive Pharmacologic Treatments for Episodic Migraine in Adults. J Gen Intern Med. 2013; 44. Law M, Morris JK, Jordan R, Wald N. Headaches and the Treatment of Blood Pressure Results From a Meta-Analysis of 94 Randomized Placebo-Controlled Trials With 24 000 Participants. Circulation. 2005;112:2301–6. 45. Linde K, Rossnagel K, Erskine A. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2012;(11):1–80. 46. Markley HG. Verapamil and Migraine Prophylaxis: Mechanisms and Efficacy. Am J Med. 1991;90. 47. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. 2001. 48. Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014;1–10. 49. Silberstein SD, Holland S, Freitag F. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78:1337–45. 50. Banzi R, Cusi C, Randazzo C, Sterzi R, Tedesco D, Moja L. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults (Review). Cochrane Database Syst Rev. 2016;(4):1–56. 51. Linde M, Mulleners W, Chronicle E, McCrocy D. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults (Review). 2013;(6):1–52. 52. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults (Review). cochrane Collab. 2013;(6):1–109. 53. Schwedt TJ. Preventive Therapy of Migraine. Contin Lifelong Learn Neurol. 2018;24(4-Headache):1052–65. 54. Loder EW, Robbins MS. Monoclonal Antibodies for Migraine Prevention Progress, but Not a Panacea Downloaded From: by a UNIVERSITY OF ADELAIDE LIBRARY User on 05/15/2018. JAMA May. 2018;15. 55. Diener HC, Dodick DW, Aurora SK, Degryse RE, Lipton RB, Silberstein SD, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial on behalf of the PREEMPT 2 Chronic Migraine Study Group. Cephalalgia. 2010;30:804–14. 56. D’onofrio F, Raimo S, Spitaleri D, Casucci G, Gennaro Bussone •. Usefulness of nutraceuticals in migraine prophylaxis. Neuro Sci. 2017;38:S117–20. 57. Verhagen, A. P., Damen, L., Berger, M. Y., Lenssinck, M. L., Passchier, J., & Kroes, B. W. (2010). Treatment of tension type headache: paracetamol and NSAIDs work: a systematic review. Nederlands Tijdschrift voor Geneeskunde, 154, [A1924]. 58. Lipton RB, Diener H-C, Robbins MS, Garas SY, Patel K. Caffeine in the management of patients with headache. J Headache Pain. 2017;18:1–11. 59. Weinman D, Nicastro O, Akala O, Friedman BW. Parenteral Treatment of Episodic Tension-Type Headache: A Systematic Review. Headache. 2014;54:260–8. 60. Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J. EFNS guideline on the treatment of tension-type headache - Report of an EFNS task force. Eur J Neurol. 2010;17(11):1318–25. 61. Ashina S, Bendtsen L, Jensen R. Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. Pain. 2004;108(1–2):108–14. 62. Jackson JL, Mancuso JM, Nickoloff S, Bernstein R, Kay C. Tricyclic and Tetracyclic Antidepressants for the Prevention of Frequent Episodic or Chronic Tension-Type Headache in Adults: A Systematic Review and Meta-Analysis. J Gen Intern Med. 2017;32(12):1351–8. 63. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders: Report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology. 2012;78(13):1009–15. 64. Donofrio P. Guillan Barre Syndrome. Contin Lifelong Learn Neurol. 2017;23(5):1295–309. 65. Hughes RAC, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016;2016(10). 66. Hughes RAC. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet. 1997;349(9047):225–30. 67. Zaeem Z, Siddiqi ZA, Zochodne DW. Autonomic involvement in Guillain–Barré syndrome: an update. Clin Auton Res [Internet]. 2019;29(3):289–99. 68. Greene-Chandos D, Torbey M. Critical Care of Neuromuscular Disorders. Contin Lifelong Learn Neurol. 2018;24(6):1753–75. 69. Ruts L, Drenthen J, Jongen JLM, Hop WCJ, Visser GH, Jacobs BC, et al. Pain in Guillain-Barré syndrome: A long-term follow-up study. Neurology. 2010;75(16):1439–47. 70. Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, et al. Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018;33(1):75–87. 71. Rajput AH, Rajput A. Medical Treatment of Essential Tremor. J Cent Nerv Syst Dis. 2014;6:29–39. 72. Sasso E, Perucca E, Fava R, Calzetti S. Primidone in the long-term treatment of essential tremor: A prospective study with computerized quantitative analysis. Vol. 13, Clinical Neuropharmacology. 1990. p. 67–76. 73. Calzetti S, Sasso E, Baratti M, Fava R. Clinical and computer‐based assessment of long‐term therapeutic efficacy of propranolol in essential tremor. Acta Neurol Scand. 1990;81(5):392–6. 74. Leigh PN, Jefferson D, Twomey A, Marsden CD. Beta-adrenoreceptor mechanisms in essential tremor; A double-blind placebo controlled trial of metoprolol, sotalol and atenolol. J Neurol Neurosurg Psychiatry. 1983;46(8):710–5. 75. Koller WC. Nadolol in essential tremor. Neurology [Internet]. 1983 Aug 1;33(8):1076 LP – 1076. 76. Samotus O, Rahimi F, Lee J, Jog M. Functional ability improved in essential tremor by incobotulinumtoxina injections using kinematically determined biomechanical patterns - A new future. PLoS One. 2016;11(4):1–17. 77. Ibañez J, González De La Aleja J, Gallego JA, Romero JP, Saíz-Díiaz RA, Benito-León J, et al. Effects of alprazolam on cortical activity and tremors in patients with essential tremor. PLoS One. 2014;9(3):3–10. 78. Biary N, Koller W. Kinetic predominant essential tremor. Neurology [Internet]. 1987 Mar 1;37(3):471 LP – 471. 79. Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, et al. Topiramate in essential tremor: A double-blind, placebo-controlled trial. Neurology. 2006;66(5):672–7. 79. Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, et al. Topiramate in essential tremor: A double-blind, placebo-controlled trial. Neurology. 2006;66(5):672–7. 80. Gironell A, Kuliscvsky J, Barbanoj M, Lopcz-Villegas D, Heniández G, Pascual-Sedano B. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol. 1999;56(4):475–80. 81. Louis E. Tremor. Continuum (N Y). 2019;25:959–75. 82. Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27(1):27–42. 83. Dell’Agnello G, Ceravolo R, Nuti A, Bellini G, Piccinni A, D’Avino C, et al. SSRIs do not worsen Parkinson’s disease: Evidence from an open-label, prospective study. Clin Neuropharmacol. 2001;24(4):221–7. 84. Morgante L, Epifanio A, Spina E, Di Rosa AE, Zappia M, Basile G, et al. Quetiapine versus clozapine: A preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson’s disease. Neurol Sci. 2002;23(SUPPL. 2):89–90. 85. Chen JJ. Treatment of psychotic symptoms in patients with Parkinson disease. Ment Heal Clin. 2017;7(6):262–70. 86. Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, et al. Monoamine oxidase type B inhibitors in early Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patients. Papers. 2004;2–7. 87. Rascal O, DJ B, Melamed O, Ortel W, Powe W, Stocci F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): Lancet. 2005;947–54. 88. Amantadine and Other Antiglutamate Agents. 2Movement Disord. 2002;17(4):S13–22. 89. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, et al. Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson’s Disease. 2Movement Disord. 2010;25:I357–63. 90. Katzenschlager R, Sampaio C, Lees CJ. Anticholinergics for symptomatic management of Parkinson´sParkinson´s disease (Review). cochrane. 2009;(1):1–20. 91. Hilten van. Dopamine agonist therapy in early Parkinson’s disease. cochrane. 2009;(1):1–89. 92. Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Western Hos-pital T, et al. Levodopa and the Progression of Parkinson’s Disease. New Engl J Med Engl J Med. 2004;2498–508. 93. Deleu D, Hanssens Y, Northway MG. Subcutaneous Apomorphine An Evidence-Based Review of its Use in Parkinson’s Disease. Vol. 21, Drugs Aging. 2004. 94. Nelson BSE, Varelas PN. Status Epilepticus, Refractory Status Epilepticus, and Super-refractory Status Epilepticus. Continuum (N Y). 2018;24:1683–707. 95. Abou-Khalil BW, Bassel D, Abou-Khalil W, Abou-Khalil D. Antiepilepticos 2019. Contin (Minneap Minn). 2019;25(April):508–36. 96. Pack AM. Epilepsy Overview and Revised Classification of Seizures and Epilepsies. Contin Lifelong Learn Neurol. 2019;25(2):306–21. 97. Vanhaerents S, Gerard EE. Epilepsy Emergencies: Status Epilepticus, Acute Repetitive Seizures, and Autoimmune Encephalitis. Contin Lifelong Learn Neurol. 2019;25(2):454–76. 98. Garcia-Monco JC. Tuberculosis of the central nervous system. Enceph Diagnosis Treat. 2007;(October):283–303. 99. Shetty AK, Maldonado YA. Neurologic complications of human immunodeficiency virus infection. Continuum (N Y). 2017;523–33. 100. Bharucha T, Houlihan CF, Breuer J. Herpesvirus Infections of the Central Nervous System. Semin Neurol. 2019;39(3):369–82. 101. Chow F. Brain and Spinal Epidural Abscess. Contin Lifelong Learn Neurol. 2018;24(5, Neuroinfectious Disease):1327–48. 102. Davis LE. Acute Bacterial Meningitis. Contin Lifelong Learn Neurol. 2018;24(5, Neuroinfectious Disease):1264–83. 103. Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, et al. The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008;47(3):303–27. 104. Centers for Disease Control and Prevention. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults. AIDSinfo. 2015;408. 105. Halperin JJ. Neuroborreliosis and Neurosyphilis. Contin Lifelong Learn Neurol. 2018;24(5, Neuroinfectious Disease):1439–58.
dc.rights.spa.fl_str_mv Derechos reservados - Universidad Nacional de Colombia
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.license.spa.fl_str_mv Atribución-NoComercial-SinDerivadas 4.0 Internacional
dc.rights.spa.spa.fl_str_mv Acceso abierto
dc.rights.uri.spa.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv Atribución-NoComercial-SinDerivadas 4.0 Internacional
Derechos reservados - Universidad Nacional de Colombia
Acceso abierto
http://creativecommons.org/licenses/by-nc-nd/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 83
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.coverage.sucursal.spa.fl_str_mv Universidad Nacional de Colombia - Sede Bogotá
dc.publisher.branch.spa.fl_str_mv Universidad Nacional de Colombia - Sede Bogotá
institution Universidad Nacional de Colombia
bitstream.url.fl_str_mv https://repositorio.unal.edu.co/bitstream/unal/75570/1/1090427413.2020.pdf
https://repositorio.unal.edu.co/bitstream/unal/75570/3/license.txt
https://repositorio.unal.edu.co/bitstream/unal/75570/4/license_rdf
https://repositorio.unal.edu.co/bitstream/unal/75570/5/1090427413.2020.pdf.jpg
bitstream.checksum.fl_str_mv af489da2dda24b1dbda84cca51134efd
6f3f13b02594d02ad110b3ad534cd5df
4460e5956bc1d1639be9ae6146a50347
8b02f0be2db88440e81eb9b115161b8f
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad Nacional de Colombia
repository.mail.fl_str_mv repositorio_nal@unal.edu.co
_version_ 1814089361931632640
spelling Atribución-NoComercial-SinDerivadas 4.0 InternacionalDerechos reservados - Universidad Nacional de ColombiaAcceso abiertohttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Fernández Escobar, William124b17e3-216c-4132-995a-d16b694b56be-1Hernández Rojas, Enrique Steff3869c2f9-2642-4cfb-97b1-e1f36b621b282020-02-10T14:59:25Z2020-02-10T14:59:25Z2020-02-06https://repositorio.unal.edu.co/handle/unal/75570Justificación: Muchas veces son médicos y/o especialistas en proceso de formación, médicos generales en urgencias y consulta externa, o especialidades como Medicina de Urgencias, Medicina Interna, Neurocirugía y/o Neurología los primeros respondientes, en muchos casos sin el entrenamiento suficiente y la afinidad necesaria por las neurociencias, para afrontar la complejidad que puede representar una enfermedad neurológica. Una herramienta informática, diseñada como aplicación (“app”) para dispositivos móviles, representa un material valioso para profesionales de la salud, estudiantes y, por supuesto, beneficioso para pacientes. Uno de los motivos por los cuales se plantea el desarrollo de este proyecto, es el hecho de no haber encontrado aplicaciones móviles centradas en el manejo farmacológico de enfermedades neurológicas en búsquedas previamente realizadas. La necesidad de una guía práctica enfocada en este aspecto lo convierte en una herramienta innovadora. Objetivo: Desarrollar una herramienta informática a manera de aplicación móvil, con la finalidad de guiar al profesional de la salud en el manejo farmacológico de las enfermedades neurológicas más prevalentes. Metodología: Se buscó sistemáticamente tratamientos farmacológicos recientes y actualizados en enfermedades neurológicas, teniendo en cuenta guías europeas, americanas y colombianas. Se diseñó una interfaz disponible para dispositivos móviles que cuenten con sistema operativo Android, en idioma español. Resultados: Creación de aplicación móvil ‘NeuroDosis’, brindando información concisa para la asistencia en la toma de decisiones por parte del clínico. Explicación breve del arsenal farmacológico indicado (mecanismo de acción, dosis, efectos adversos más frecuentes, contraindicaciones y recomendaciones prácticas) en las patologías neurológicas más prevalentes en pacientes adultos.Justification: Many times, are physicians and / or specialists in process of training, general practitioners in the emergency department and outpatient clinics, or specialties such as Emergency Medicine, Internal Medicine, Neurosurgery and / or Neurology, the first responders, in many cases without sufficient training and the necessary affinity for neurosciences, to face the complexity that a neurological disease can represent. A computer tool, developed as an application (“app”) for mobile devices, represents a valuable material for health professionals, students and, of course, beneficial for patients. One of the reasons for the development of this project is the fact of not having found mobile applications focused on the pharmacological management of neurological diseases in previously conducted searches. The need for a practical guide focused on this aspect made it an innovative tool. Objective: To develop a computer tool as a mobile application, with the purpose of guiding the health professional in the pharmacological management of the most prevalent neurological diseases. Methodology: Recent and revised pharmacological treatments in neurological diseases were systematically sought, taking into account the European, American and Colombian guidelines. An available interface was designed for mobile devices that have an Android operating system, in Spanish. Results: Creation of a mobile application, ‘NeuroDosis’, providing concise information for decision-making assistance by the clinician. Brief explanation of the indicated pharmacological arsenal (mechanism of action, dose, most frequent adverse effects, contraindications and practical recommendations) in the most prevalent neurological pathologies in adult patients.Especialista en Neurología Clínica.83application/pdfspaMedicina y saludNeurologyTreatmentApplicationDrugsNeurologíaTratamientoAplicaciónMedicamentosAppDesarrollo de herramienta informática para el fácil acceso a tratamientos farmacológicos en neurologíaDocumento de trabajoinfo:eu-repo/semantics/workingPaperinfo:eu-repo/semantics/acceptedVersionhttp://purl.org/coar/resource_type/c_8042Texthttp://purl.org/redcol/resource_type/WPUniversidad Nacional de Colombia - Sede BogotáUniversidad Nacional de Colombia - Sede Bogotá1. Huckvale K, Prieto JT, Tilney M, Benghozi PJ, Car J. Unaddressed privacy risks in accredited health and wellness apps: A crosssectional systematic assessment. BMC Med. 2015;13:214. 2. Oh, H., Rizo, C., Enkin, M., Jadad, A. (2005). What is eHealth (3): A Systematic Review of Published Definitions. Journal of Medical Internet Research, 7(1), e1. 3. Pradilla A., G., Vesga A., B. E., & León-Sarmiento, F. E. (2003). Estudio neuroepidemiológico nacional (EPINEURO) colombiano. Revista Panamericana de Salud Pública, 14(2), 104–111. 4. Restrepo, J., Aldana, R., Álvarez, et. Al (2017). Percepción de neurofobia en estudiantes de último año de Medicina en una universidad privada Neurophobic perception in last year medical students at a private university. Acta Neurológica Colombiana, 33(1), 63–67. 5. Jozefowicz R. Neurophobia: The Fear of Neurology Among Medical Students. Archives of Neurology. 1994;51(4):328-29. 6. Moringo D, Fleitas D, Morel Pirelli M, V. G. (2017). Neurofobia en estudiantes de postgrado en Medicina Interna. Rev. Virtual Soc. Parag. Med. Int., 04(2), 42–48. 7. Dorsey, E. R., Chan, Y. F., Mcconnell, M. V., Shaw, S. Y., Trister, A. D., & Friend, S. H. (2017). The use of smartphones for health research. Academic Medicine, 92(2), 157–160. 8. Albers GW, Alberts MJ, Chaturvedi S, Feldmann F; E, Hatsukami TS, Higashida RT, et al. Definition and Evaluation of Transient Ischemic Attack A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiov. AHA/ASA Sci Statement. 2009;40:2276–93. 9. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Vol. 50, Stroke. 2019. 344–418 p. 10. Prasad K, Siemieniuk R, Hao Q, Guyat G, O’Donnell M, Lytvyn L, et al. Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. BMJ Rapid Recomm. 2018; 11. Amarenco P, Labreuche J, Lavallée P, Touboul P-J. Statins in Stroke Prevention and Carotid Atherosclerosis Systematic Review and Up-to-Date Meta-Analysis. 2004; 12. Amarenco P, Diderot Uni-versity D, Bogousslavsky J, Rudolph AE, York N, Sillesen H, et al. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators* A BS TR AC T. 2006. 13. Rabinstein AA. Tratamiento Agudo De Evc Isquemico. Continuum (N Y). 2017;(February):62–81. 14. Coutts SB. Diagnosis and Management of Transient Ischemic Attack. Contin Lifelong Learn Neurol. 2017;23(1):82–92. 15. Demaerschalk BM. Remote Evaluation of the Patient with Acute Stroke. Contin Lifelong Learn Neurol. 2017;23(1):259–67. 16. Cj D, Derry S, Ra M. Sumatriptan (all routes of administration) for acute migraine attacks in adults-overview of Cochrane reviews (Review). 2014; 17. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat P Tfelt-Hansen. Cephalalgia. 1998;532–8. 18. Bird S, Derry S, Ra M. Zolmitriptan for acute migraine attacks in adults (Review). cochrane. 2014; 19. Brandes JL, Kudrow D, Stark SR, Phillip O’carroll C, Adelman JU, O’donnell FJ, et al. Sumatriptan-Naproxen for Acute Treatment of Migraine A Randomized Trial. Vol. 297, JAMA. 2007. 20. Vane J. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drug. Vol. 231, Nature new biology. 1971. 21. Taggart E, Doran S, Kokotillo A, Campbell S, Villa-Roel C, Rowe BH, et al. Ketorolac in the Treatment of Acute Migraine: A Systematic Review. Am Headache Soc. 2013; 22. Derry S, Ra M. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults (Review). Cochrane Database Syst Rev. 2013; 23. Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E, et al. Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient SECTION III. Can J Neurol Sci. 2013;s33–62. 24. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous Dipyrone in the Acute Treatment of Migraine Without Aura and Migraine with Aura: A Randomized, Double Blind, Placebo Controlled Study. Headache. 2002;42:862–71. 25. Hering R, Couturier E, Steiner T. Intramuscular diclofenac in late treatment of migraine. 1996. 26. Engindeniz Z, Demircan C, Karli N, Armagan E, Bulut M, Aydin T, et al. Intramuscular tramadol vs. diclofenac sodium for the treatment of acute migraine attacks in emergency department: a prospective, randomised, double-blind study. headache Pain. 2005;6:143–8. 27. Muñoz J, Volcy M, Sobrino F, Ramirez S, Uribe B, Pradilla G, et al. Consenso de expertos de la Asociación Colombiana de Neurología para el tratamiento preventivo y agudo de la migraña Expert consensus on the preventive and acute treatment of migraine on behalf of the Colombian Association of Neurology Artículo original. Vol. 30, Acta Neurol Colomb. 2014. 28. Silberstein SD, Mccrory DC. Ergotamine and Dihydroergotamine: History, Pharmacology, and Efficacy. Headache. 2003. 29. Langer-Gould AM, Anderson WE, Armstrong MJ, Cohen AB, Eccher MA, Iverson DJ, et al. The American Academy of Neurology’s Top Five Choosing Wisely recommendations. Am Acad ofNeurology. 2013;81:1004–11. 30. Blumenfeld A, Ashkenazi A, Napchan U, Bender SD, Klein BC, Berliner R, et al. Expert Consensus Recommendations for the Performance of Peripheral Nerve Blocks for Headaches-A Narrative Review. Headache. 2013;53:437–46. 31. Robbins MS, Robertson CE, Kaplan E, Ailani J, Charleston L, Kuruvilla D, et al. The Sphenopalatine Ganglion: Anatomy, Pathophysiology, and Therapeutic Targeting in Headache. Headache. 2015;56:240–58. 32. Colman I, Friedman BW, Brown MD, Innes G, Grafstein E, Roberts TE, et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BJM. 2008;1–7. 33. Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, et al. Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache. 2016;56:911–40. 34. Vécsei L, Szok D, Nyári A, Tajti J. Treating status migrainosus in the emergency setting: what is the best strategy? Expert Opin Pharmacother. 2018;1–9. 35. Demirkaya eref, Vural O, Dora B, Akif Topçuo lu M. Efficacy of Intravenous Magnesium Sulfate in the Treatment of Acute Migraine Attacks. Headache. 2001;41:171–7. 36. Bigal ME, Bordini CA, Speciali JG. intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med. 2002;23(2):141–8. 11 37. Léger P, Lortie G. Towards evidence-based emergency medicine: metoclopramide or prochlorperazine for headache in acute migraine? Emerg Med J. 2013;30:595–6. 38. Friedman BW, Eddie Irizarry M, Solorzano C, Alexander Latev P, Rosa K, Zias E, et al. Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. Neurology. 2017;89:1–8. 39. Colman I, Brown MD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004;1–5. 40. Honkaniemi J, Liimatainen S, Rainesalo S, Sulavuori S. Haloperidol in the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache. 2006;46:781–7. 41. The International Classification of Headache Disorders, 3rd edition Copyright. Cephalalgia. 2018;38:1–211. 42. Pringsheim T, Davenport WJ, Mackie G, Worthington I, Aubé M, Christie SN, et al. Canadian Headache Society Guideline for Migraine Prophylaxis. Vol. 39. 2012. 43. Shamliyan TA, Choi J-Y, Ramakrishnan R, Biggs Miller J, Wang S-Y, Taylor FR, et al. Preventive Pharmacologic Treatments for Episodic Migraine in Adults. J Gen Intern Med. 2013; 44. Law M, Morris JK, Jordan R, Wald N. Headaches and the Treatment of Blood Pressure Results From a Meta-Analysis of 94 Randomized Placebo-Controlled Trials With 24 000 Participants. Circulation. 2005;112:2301–6. 45. Linde K, Rossnagel K, Erskine A. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2012;(11):1–80. 46. Markley HG. Verapamil and Migraine Prophylaxis: Mechanisms and Efficacy. Am J Med. 1991;90. 47. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. 2001. 48. Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014;1–10. 49. Silberstein SD, Holland S, Freitag F. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78:1337–45. 50. Banzi R, Cusi C, Randazzo C, Sterzi R, Tedesco D, Moja L. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults (Review). Cochrane Database Syst Rev. 2016;(4):1–56. 51. Linde M, Mulleners W, Chronicle E, McCrocy D. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults (Review). 2013;(6):1–52. 52. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults (Review). cochrane Collab. 2013;(6):1–109. 53. Schwedt TJ. Preventive Therapy of Migraine. Contin Lifelong Learn Neurol. 2018;24(4-Headache):1052–65. 54. Loder EW, Robbins MS. Monoclonal Antibodies for Migraine Prevention Progress, but Not a Panacea Downloaded From: by a UNIVERSITY OF ADELAIDE LIBRARY User on 05/15/2018. JAMA May. 2018;15. 55. Diener HC, Dodick DW, Aurora SK, Degryse RE, Lipton RB, Silberstein SD, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial on behalf of the PREEMPT 2 Chronic Migraine Study Group. Cephalalgia. 2010;30:804–14. 56. D’onofrio F, Raimo S, Spitaleri D, Casucci G, Gennaro Bussone •. Usefulness of nutraceuticals in migraine prophylaxis. Neuro Sci. 2017;38:S117–20. 57. Verhagen, A. P., Damen, L., Berger, M. Y., Lenssinck, M. L., Passchier, J., & Kroes, B. W. (2010). Treatment of tension type headache: paracetamol and NSAIDs work: a systematic review. Nederlands Tijdschrift voor Geneeskunde, 154, [A1924]. 58. Lipton RB, Diener H-C, Robbins MS, Garas SY, Patel K. Caffeine in the management of patients with headache. J Headache Pain. 2017;18:1–11. 59. Weinman D, Nicastro O, Akala O, Friedman BW. Parenteral Treatment of Episodic Tension-Type Headache: A Systematic Review. Headache. 2014;54:260–8. 60. Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J. EFNS guideline on the treatment of tension-type headache - Report of an EFNS task force. Eur J Neurol. 2010;17(11):1318–25. 61. Ashina S, Bendtsen L, Jensen R. Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. Pain. 2004;108(1–2):108–14. 62. Jackson JL, Mancuso JM, Nickoloff S, Bernstein R, Kay C. Tricyclic and Tetracyclic Antidepressants for the Prevention of Frequent Episodic or Chronic Tension-Type Headache in Adults: A Systematic Review and Meta-Analysis. J Gen Intern Med. 2017;32(12):1351–8. 63. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders: Report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology. 2012;78(13):1009–15. 64. Donofrio P. Guillan Barre Syndrome. Contin Lifelong Learn Neurol. 2017;23(5):1295–309. 65. Hughes RAC, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016;2016(10). 66. Hughes RAC. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet. 1997;349(9047):225–30. 67. Zaeem Z, Siddiqi ZA, Zochodne DW. Autonomic involvement in Guillain–Barré syndrome: an update. Clin Auton Res [Internet]. 2019;29(3):289–99. 68. Greene-Chandos D, Torbey M. Critical Care of Neuromuscular Disorders. Contin Lifelong Learn Neurol. 2018;24(6):1753–75. 69. Ruts L, Drenthen J, Jongen JLM, Hop WCJ, Visser GH, Jacobs BC, et al. Pain in Guillain-Barré syndrome: A long-term follow-up study. Neurology. 2010;75(16):1439–47. 70. Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, et al. Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018;33(1):75–87. 71. Rajput AH, Rajput A. Medical Treatment of Essential Tremor. J Cent Nerv Syst Dis. 2014;6:29–39. 72. Sasso E, Perucca E, Fava R, Calzetti S. Primidone in the long-term treatment of essential tremor: A prospective study with computerized quantitative analysis. Vol. 13, Clinical Neuropharmacology. 1990. p. 67–76. 73. Calzetti S, Sasso E, Baratti M, Fava R. Clinical and computer‐based assessment of long‐term therapeutic efficacy of propranolol in essential tremor. Acta Neurol Scand. 1990;81(5):392–6. 74. Leigh PN, Jefferson D, Twomey A, Marsden CD. Beta-adrenoreceptor mechanisms in essential tremor; A double-blind placebo controlled trial of metoprolol, sotalol and atenolol. J Neurol Neurosurg Psychiatry. 1983;46(8):710–5. 75. Koller WC. Nadolol in essential tremor. Neurology [Internet]. 1983 Aug 1;33(8):1076 LP – 1076. 76. Samotus O, Rahimi F, Lee J, Jog M. Functional ability improved in essential tremor by incobotulinumtoxina injections using kinematically determined biomechanical patterns - A new future. PLoS One. 2016;11(4):1–17. 77. Ibañez J, González De La Aleja J, Gallego JA, Romero JP, Saíz-Díiaz RA, Benito-León J, et al. Effects of alprazolam on cortical activity and tremors in patients with essential tremor. PLoS One. 2014;9(3):3–10. 78. Biary N, Koller W. Kinetic predominant essential tremor. Neurology [Internet]. 1987 Mar 1;37(3):471 LP – 471. 79. Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, et al. Topiramate in essential tremor: A double-blind, placebo-controlled trial. Neurology. 2006;66(5):672–7. 79. Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, et al. Topiramate in essential tremor: A double-blind, placebo-controlled trial. Neurology. 2006;66(5):672–7. 80. Gironell A, Kuliscvsky J, Barbanoj M, Lopcz-Villegas D, Heniández G, Pascual-Sedano B. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol. 1999;56(4):475–80. 81. Louis E. Tremor. Continuum (N Y). 2019;25:959–75. 82. Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27(1):27–42. 83. Dell’Agnello G, Ceravolo R, Nuti A, Bellini G, Piccinni A, D’Avino C, et al. SSRIs do not worsen Parkinson’s disease: Evidence from an open-label, prospective study. Clin Neuropharmacol. 2001;24(4):221–7. 84. Morgante L, Epifanio A, Spina E, Di Rosa AE, Zappia M, Basile G, et al. Quetiapine versus clozapine: A preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson’s disease. Neurol Sci. 2002;23(SUPPL. 2):89–90. 85. Chen JJ. Treatment of psychotic symptoms in patients with Parkinson disease. Ment Heal Clin. 2017;7(6):262–70. 86. Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, et al. Monoamine oxidase type B inhibitors in early Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patients. Papers. 2004;2–7. 87. Rascal O, DJ B, Melamed O, Ortel W, Powe W, Stocci F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): Lancet. 2005;947–54. 88. Amantadine and Other Antiglutamate Agents. 2Movement Disord. 2002;17(4):S13–22. 89. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, et al. Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson’s Disease. 2Movement Disord. 2010;25:I357–63. 90. Katzenschlager R, Sampaio C, Lees CJ. Anticholinergics for symptomatic management of Parkinson´sParkinson´s disease (Review). cochrane. 2009;(1):1–20. 91. Hilten van. Dopamine agonist therapy in early Parkinson’s disease. cochrane. 2009;(1):1–89. 92. Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Western Hos-pital T, et al. Levodopa and the Progression of Parkinson’s Disease. New Engl J Med Engl J Med. 2004;2498–508. 93. Deleu D, Hanssens Y, Northway MG. Subcutaneous Apomorphine An Evidence-Based Review of its Use in Parkinson’s Disease. Vol. 21, Drugs Aging. 2004. 94. Nelson BSE, Varelas PN. Status Epilepticus, Refractory Status Epilepticus, and Super-refractory Status Epilepticus. Continuum (N Y). 2018;24:1683–707. 95. Abou-Khalil BW, Bassel D, Abou-Khalil W, Abou-Khalil D. Antiepilepticos 2019. Contin (Minneap Minn). 2019;25(April):508–36. 96. Pack AM. Epilepsy Overview and Revised Classification of Seizures and Epilepsies. Contin Lifelong Learn Neurol. 2019;25(2):306–21. 97. Vanhaerents S, Gerard EE. Epilepsy Emergencies: Status Epilepticus, Acute Repetitive Seizures, and Autoimmune Encephalitis. Contin Lifelong Learn Neurol. 2019;25(2):454–76. 98. Garcia-Monco JC. Tuberculosis of the central nervous system. Enceph Diagnosis Treat. 2007;(October):283–303. 99. Shetty AK, Maldonado YA. Neurologic complications of human immunodeficiency virus infection. Continuum (N Y). 2017;523–33. 100. Bharucha T, Houlihan CF, Breuer J. Herpesvirus Infections of the Central Nervous System. Semin Neurol. 2019;39(3):369–82. 101. Chow F. Brain and Spinal Epidural Abscess. Contin Lifelong Learn Neurol. 2018;24(5, Neuroinfectious Disease):1327–48. 102. Davis LE. Acute Bacterial Meningitis. Contin Lifelong Learn Neurol. 2018;24(5, Neuroinfectious Disease):1264–83. 103. Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, et al. The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008;47(3):303–27. 104. Centers for Disease Control and Prevention. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults. AIDSinfo. 2015;408. 105. Halperin JJ. Neuroborreliosis and Neurosyphilis. Contin Lifelong Learn Neurol. 2018;24(5, Neuroinfectious Disease):1439–58.ORIGINAL1090427413.2020.pdf1090427413.2020.pdfapplication/pdf832962https://repositorio.unal.edu.co/bitstream/unal/75570/1/1090427413.2020.pdfaf489da2dda24b1dbda84cca51134efdMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-83991https://repositorio.unal.edu.co/bitstream/unal/75570/3/license.txt6f3f13b02594d02ad110b3ad534cd5dfMD53CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://repositorio.unal.edu.co/bitstream/unal/75570/4/license_rdf4460e5956bc1d1639be9ae6146a50347MD54THUMBNAIL1090427413.2020.pdf.jpg1090427413.2020.pdf.jpgGenerated Thumbnailimage/jpeg4997https://repositorio.unal.edu.co/bitstream/unal/75570/5/1090427413.2020.pdf.jpg8b02f0be2db88440e81eb9b115161b8fMD55unal/75570oai:repositorio.unal.edu.co:unal/755702024-03-14 23:08:25.087Repositorio Institucional Universidad Nacional de Colombiarepositorio_nal@unal.edu.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

Publicaciones similares